IL6R and rheumatoid arthritis: No findings were associated with an increased discontinuation rate for anti-IL6R, while multivariate analysis showed a RA diagnosis over 65 years as independent factors associated with discontinuation for JAKi, the number of comorbidities for RTX, and a high CDAI for TNFi.